Elicad Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.00 M
- Satisfied Charges ₹ 1.00 M
- Revenue Growth 129902.98%
- Profit Growth 101199.17%
- Ebitda 481175.63%
- Net Worth 188474.91%
- Total Assets 115540.46%
About Elicad Pharmaceuticals
Elicad Pharmaceuticals Private Limited (EPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 10 January 2018 (Seven years and one month 12 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹6.00 M. The company has closed loans amounting to ₹1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Nishit Ribadia, Manoj Bhayani, Gaurang Bhatt, and One other member serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999GJ2018PTC100473
- Company No.
100473
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jan 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Elicad Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nishit Ribadia  | Director | 10-Jan-2018 | Current |
| Manoj Bhayani | Director | 10-Jan-2018 | Current |
| Gaurang Bhatt | Director | 10-Jan-2018 | Current |
| Hiteshkumar Patel | Director | 10-Jan-2018 | Current |
Financial Performance of Elicad Pharmaceuticals.
Elicad Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 129902.98% increase. The company also saw a substantial improvement in profitability, with a 101199.17% increase in profit. The company's net worth Soared by an impressive increase of 188474.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elicad Pharmaceuticals?
Unlock access to Elicad Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹6.00 M
₹1.00 M
Charges Breakdown by Lending Institutions
- Others : 0.60 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Feb 2022 | Others | ₹6.00 M | Open |
| 25 Feb 2019 | Others | ₹1.00 M | Satisfied |
How Many Employees Work at Elicad Pharmaceuticals?
Elicad Pharmaceuticals has a workforce of 19 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elicad Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elicad Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.